VERIGRAFT Advances First Potential Curative Treatment for CVI into Pivotal Phase II/III Trial

GOTHENBURG, Sweden, March 25, 2026 /PRNewswire/ -- VERIGRAFT, a Swedish clinical-stage biotechnology company pioneering personalized, fully biological therapies, today announced the initiation of a pivotal Phase II/III trial of its P-TEV (personalized tissue engineered vein) in patients with chronic venous insuffici…

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.